Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.
According to data presented by NewLink, all 10 newly diagnosed DIPG patients in a phase I study demonstrated initial symptomatic improvement after treatment with indoximod and chemotherapy.
The FY18 Defense Appropriations Act provides $80 million to the Department of Defense Peer Reviewed Cancer Research Program to support innovative, high-impact cancer research.
The American Society of Clinical Oncology and the European Society for Medical Oncology are calling on leaders and health ministers of the 193 United Nations member countries to reduce the burden of all non-communicable diseases including cancer.
Pooja Ghatalia was named an assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center. Ghatalia will join the faculty after graduating from a three-year hematology/oncology fellowship, which she began at Fox Chase in 2015.
The NCI Board of Scientific Advisors approved 10 concepts, including eight new concepts and two re-issued Requests for Applications in a joint meeting with the National Cancer Advisory Board on June 26 and 27.
In 2010, Otis Brawley and I were in the midst of writing a book about the state of cancer care in America.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has approved Braftovi capsules in combination with Mektovi tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.
Kymab Group Ltd. announced a clinical trial agreement with F. Hoffmann-La Roche Ltd.
